Feasibility study of type Ⅰ hysterectomy in stage Ⅰ A cervical cancer
10.3760/cma.j.issn.1006-9801.2013.10.003
- VernacularTitle:Ⅰ型子宫切除术用于ⅠA期子宫颈癌的可行性研究
- Author:
Yunshui YUAN
;
Longyang LIU
;
Juanjuan YI
;
Daomei NIE
;
Huizhen CHEN
- Publication Type:Journal Article
- Keywords:
Uterine cervical neoplasms;
Neoplasm invasiveness;
Type Ⅰ hysterectomy;
Feasibility study
- From:
Cancer Research and Clinic
2013;25(10):659-662
- CountryChina
- Language:Chinese
-
Abstract:
Objective To compare the efficacy and complications of the two surgical methods (between type Ⅰ hysterectomy and type Ⅱ hysterectomy),and to explore the feasibility of type Ⅰ hysterectomy in stage ⅠA cervical cancer.Methods The study group,92 cases(48 cases of stage ⅠA1,44 cases of stage ⅠA2) were performed with type Ⅰ hysterectomy plus selective pelvic lymph node dissection;the control group,93 cases (49 cases of stage ⅠA1,44 cases of ⅠA2) were performed with type Ⅱ hysterectomy plus selective pelvic lymph node dissection.Results The survival rate of 5 years and 10 years in study group were 100 ％ (92/92),100 ％ (74/74) and that in control group were 100 ％ (93/93),100 ％(66/66),respectively.There were no signicant difference between the two group (both P ＞ 0.05).When compared with the control group,the urinary tract infection of the study group was significantly reduced (0 versus 13.99 ％,P ＜ 0.05).Moreover,there were a shorter surgical duration [(96.14±17.20) min vs (116.82±16.30) min].The hemorrhage [(117.35±39.61) ml] and blood transfusion (0 ml) in study group was less common than those in control group [(201.74±46.25) ml,(82.07±16.32) ml] (all P ＜ 0.01).Conclusion There are no difference of 5-year and l0-year survival rate in stage ⅠA patients with type Ⅰ or type Ⅱ hysterectomy,however,the rate of the postoperative urinary tract infection in the former is lower than that in the latter,and also there are a shorter surgical duration,less hemorrhage and reduced blood transfusion requirements in study group.Therefore,type Ⅰ hysterectomy can be effective and applicable for the patients of stage ⅠA cervical cancer.
